论文部分内容阅读
目的 研究生长抑素(SS)、血管活性肠肽(VIP)、胃动素(MTL)在门脉高压症中的水平及其作用。方法 应用放射免疫学方法对 62例肝硬化门脉高压症患者、51例正常对照者血浆及 43份门脉高压性腹水进行SS、VIP与MTL的检测。结果 门脉高压症组血浆SS、VIP与MTL水平分别为 58 23±13 5pg/ml, 18 68±4 22pg/ml及 362 95±32 82pg/ml;正常对照组分别为 81 23±31 89pg/ml, 11 96±3 27pg/ml及 202 95±26 42pg/ml,二者差异有显著性(P<0 05)。腹水组分别为 148 03±28 41pg/ml, 14 12±3 64pg/ml及 267 43±29 04pg/ml。腹水SS、MTL高于对照组血浆含量(P<0 05)。腹水VIP与对照组血浆含量差异无显著性。肝硬化腹水患者血浆SS低于无腹水者,而VIP与MTL水平高于无腹水者(P<0 05)。VIP、MTL随着肝功能分级的发展而逐步增加。结论 血浆SS、VIP与MTL在肝硬化门脉高压症的病理生理机制中起着重要作用。
Objective To study the effects of somatostatin (SS), vasoactive intestinal peptide (VIP) and motilin (MTL) on portal hypertension. Methods 62 cases of cirrhotic patients with portal hypertension, 51 cases of normal control plasma and 43 cases of portal hypertension ascites were detected by radioimmunoassay for detection of SS, VIP and MTL. Results The plasma levels of SS, VIP and MTL in patients with portal hypertension were 58 23 ± 13 5 pg / ml, 18 68 ± 42 2 pg / ml and 362 95 ± 32 82 pg / ml, respectively. The normal control group were 81 23 ± 31 89 pg / ml, 11 96 ± 3 27pg / ml and 202 95 ± 26 42pg / ml, respectively. There was a significant difference between the two groups (P <0.05). The ascites group was 148 03 ± 28 41 pg / ml, 14 12 ± 3 64 pg / ml and 267 43 ± 29 04 pg / ml, respectively. The ascites SS and MTL were higher than those in the control group (P <0.05). Ascites VIP and control group plasma content was no significant difference. Patients with cirrhosis and ascites had lower plasma SS and VIP and MTL than those without ascites (P <0.05). VIP, MTL gradually increase with the development of liver function grading. Conclusion Plasma SS, VIP and MTL play an important role in the pathophysiology of cirrhosis and portal hypertension.